Another strong quarter for our client Alnylam Pharmaceuticals

May 1, 2025 · Business Wire

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results

Alnylam reported 28% year-over-year growth in net product revenues and a major U.S. regulatory milestone for AMVUTTRA.

• Global net product revenues of $469 million, up 28% from Q1 2024
• TTR franchise net product revenues up 36%
• FDA approval of AMVUTTRA (vutrisiran) for ATTR-CM, with the launch underway
• FDA approval of Qfitlia (fitusiran), developed with partner Sanofi, the sixth Alnylam-discovered RNAi therapeutic approved in the U.S.
• 2025 total net product revenue guidance of $2.05–$2.25 billion reiterated

Read the full release

Source: Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), via Business Wire. Figures are as reported on the release date; guidance is forward-looking and subject to the risks described in the full release.